Synonym: (3R,4R)-3,4-Dimethyl-1-[(3S)-3-hydroxy-3-cyclohexyl-propyl]-4-(3-hydroxyphenyl)piperidine; (aS,3R,4R)-a-Cyclohexyl-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinepropanol; LY-255582
CAS Number: 119193-09-8
Empirical Formula (Hill Notation): C22H35NO2
Molecular Weight: 345.52
MDL Number: MFCD00878181
Linear Formula: C22H35NO2
Product Type: Chemical
assay |
≥98% (HPLC) |
color |
white to beige |
form |
powder |
InChI |
1S/C22H35NO2/c1-17-16-23(13-11-21(25)18-7-4-3-5-8-18)14-12-22(17,2)19-9-6-10-20(24)15-19/h6,9-10,15,17-18,21,24-25H,3-5,7-8,11-14,16H2,1-2H3/t17-,21-,22+/m0/s1 |
InChI key |
LVVHEFJXPXAUDD-BULFRSBZSA-N |
originator |
Eli Lilly |
Quality Level |
100 |
SMILES string |
C[C@H]1CN(CC[C@H](O)C2CCCCC2)CC[C@@]1(C)c3cccc(O)c3 |
solubility |
DMSO: ≥15 mg/mL |
storage condition |
desiccated |
storage temp. |
2-8°C |
Application: |
LY255582 may be used in opioid receptor-mediated cell signaling studies. |
Biochem/physiol Actions: |
LY255582 inhibits the diet-associated increases in mesolimbic dopamine levels and reduces the consumption of highly-palatable food intake. |
Biochem/physiol Actions: |
LY255582 is a centrally active opioid receptor antagonist (defined as an inverse agonist in 2011 JPET paper) that inhibited weight gain in obese Zucker rats over 30 days. It is more that 5-fold selective for mu opioid receptor compared to kappa opioid receptors and 13-fold selective over delta opioid receptors. |
Features and Benefits: |
This compound is featured on the Opioid Receptors page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here . |
Features and Benefits: |
This compound was developed by Eli Lilly . To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here . |
Packaging: |
5, 25 mg in glass bottle |
RIDADR |
NONH for all modes of transport |
WGK Germany |
WGK 3 |
Flash Point(F) |
Not applicable |
Flash Point(C) |
Not applicable |
Purity |
≥98% (HPLC) |
Storage Temp. |
2-8°C |
UNSPSC |
12352200 |